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ABSTRACT 
 
The Association of Urinary Polycyclic Aromatic Hydrocarbons and Markers of 
Inflammation, Diabetes Mellitus and Cardiovascular Disease 
 
Omayma Alshaarawy 
 
 
Polycyclic aromatic hydrocarbons are potent atmospheric pollutants, released into air 
during incomplete combustion of fuel, industrial or domestic coal, wood, cigarette smoke and 
other organic materials. In addition to being carcinogenic, several animal studies have reported 
positive associations between polycyclic aromatic hydrocarbons and inflammation, oxidative 
stress and the development and progression of atherosclerosis. Occupational studies have 
reported positive associations between polycyclic aromatic hydrocarbons and cardiovascular 
morbidity and mortality. Moreover, there is evidence that polycyclic aromatic hydrocarbons may 
cause disruption of the endocrine system. It is still not clear if lower background exposure to 
polycyclic aromatic hydrocarbons, independent of the adverse health effects of smoking, is 
associated with increased risk of inflammation, diabetes mellitus and cardiovascular disease in 
the general population. We examined participants from the merged National Health and 
Nutrition Examination Survey 2001-02, 2003-2004, and 2005-2006. Our exposures of interest 
were eight urinary monohydroxy polycyclic aromatic hydrocarbons and our outcomes were 
serum markers of systemic inflammation, including: serum C-reactive protein and total white 
blood cell count, diabetes mellitus and self-reported cardiovascular disease. Urinary biomarkers 
of the low molecular weight polycyclic aromatic hydrocarbons were found to be positively 
associated with serum C-reactive protein, total white blood cell count and diabetes mellitus 
independent of potential confounders. Levels of 1-hydroxypyrene, the urinary metabolite of the 
higher molecular weight PAH, pyrene, showed a less strong association with serum C-reactive 
protein and diabetes mellitus. The evidence on the association between polycyclic aromatic 
hydrocarbons and self-reported cardiovascular disease was limited, only 1-hydroxynapthalene, 
summed biomarkers of low molecular weight polycyclic aromatic hydrocarbons,  and 1-
hydroxypyrene showed statistically significant positive associations with cardiovascular disease 
independent of potential confounders. In conclusion, this study provides evidence on the positive 
association of background exposure to polycyclic aromatic hydrocarbons and serum C-reactive 
protein, total white blood cell count, diabetes mellitus and cardiovascular disease. Further 
prospective studies are needed to replicate or refute our findings.
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INTRODUCTION 
 
Rationale for studying systemic inflammation, diabetes mellitus and CVD 
Despite advances in prevention, diagnosis and treatment, cardiovascular disease (CVD) 
remains the number one cause of mortality in United States (US) adults.[1] Diabetes mellitus is a 
major risk factor for CVD [2, 3] and the seventh leading cause of death in the US.[4] Systemic 
inflammation is considered a key risk factor for atherosclerosis and subsequent development of 
CVD.[5] Inflammation has been also known to associate with insulin resistance and diabetes 
mellitus.[6] Several studies have reported positive association between baseline elevations of the 
serum inflammatory marker C-reactive protein (CRP) and risk of CVD and diabetes mellitus.[7, 
8]  Moreover, elevation in total white blood cells (WBC) count within the normal range was 
found to be independently associated with CVD and diabetes mellitus.[9, 10]  
 
Environmental pollutants and systemic inflammation, diabetes mellitus and CVD 
Several studies have suggested that exposure to particulate matter present in ambient air 
is associated with increased CVD. Recent evidence has suggested that smaller particles and gases 
may pose a greater CVD risk, possibly through development of atherosclerosis.[11] In addition, 
studies have suggested that common environmental exposures , such as Dioxins [12] (group of 
halogenated aromatic hydrocarbons), affecting large sections of the population may be a 
determinant of diabetes risk [13, 14] as well as CVD risk.[15]  
 
Polycyclic aromatic hydrocarbons  
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Polycyclic aromatic hydrocarbons (PAHs) are environmental and occupational 
carcinogens released into air during incomplete combustion of fuel, industrial or domestic coal, 
wood, and grilled or smoked food.[16, 17] Active smoking and second-hand smoke (SHS) 
exposure are major sources of PAHs.[18] Individuals without occupational or tobacco smoke 
exposure are believed to be exposed primarily to PAHs through food contaminated with 
PAHs.[19] The total intake of PAHs in the general population has been estimated to be 3 
μg/day.[20]  
Polycyclic aromatic hydrocarbons are found within the environment in either a gaseous 
or particulate form.[21] PAHs with the lowest molecular weight (naphthalene, fluorene, and 
phenanthrene) have low vapor pressures, and are found mainly in a gaseous form. Polycyclic 
aromatic hydrocarbons with higher molecular weights (pyrene) have higher vapor pressures and 
are found in a particulate form. Individuals exposed to PAHs via inhalation of the ambient air are 
exposed to both low molecular weight (LMW) PAHs and higher molecular weight PAHs. 
Humans are also exposed to the higher molecular weight PAHs through gastrointestinal 
absorption of contaminated food or water and/or skin absorption of PAH particles.[22]  
Polycyclic aromatic hydrocarbons were found to have high affinity for lipid-rich tissues 
such as mammary and adipose tissues.[23] Irrespective of the route of administration, PAHs are 
rapidly and widely distributed in the body. Detectable levels of PAHs can be observed in most 
internal organs following exposure.[4] Researchers have examined PAHs directly in the blood 
and tissues of experimental animals. However, these methods have not been widely used for 
humans due to the high costs and the limited clinical significance of testing. The most commonly 
used biomarkers of PAH exposure are urinary monohydroxy-PAH (OH-PAH). Urinary OH-PAH 
3 
 
has been found to correlate well with levels of exposure to PAHs in the general populations.[24] 
Additional effects of human occupational exposures can be detected using urinary PAH 
biomarkers, independent of smoking.[25] 
 
PAHs and systemic inflammation, diabetes mellitus and CVD  
Considering the large number of deaths attributable to ambient air pollution, PAHs may 
be a significant contributor to the high prevalence and mortality rate of diabetes mellitus and 
cardiovascular disease. Several animal studies have reported positive associations between PAHs 
and inflammation [26, 27], oxidative stress [28, 29] and the development and progression of 
atherosclerosis.[30, 31] Exposure to PAHs triggers the Aryl hydrocarbon (AhR) –Xenobiotic 
response element (XRE) signaling pathway and causes expression of proinflammatory genes. It 
leads to inflammation that underlies development 
of atherosclerosis. Activation of the AhR–XRE 
pathway also induces expression of cytochrome 
P450 (CYP) and subsequently generates reactive 
oxygen species (ROS) and DNA adducts which 
contributes to endothelial injury and consequent 
atherosclerosis. Several studies have also 
suggested that PAHs may cause disruption of the 
endocrine system.[32]  
 
Figure 1: Masanori Kitamura and Ayumi 
Kasai, 2007 
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In addition, several occupational studies have reported positive associations between 
PAHs and cardiovascular morbidity [33, 34] and mortality.[35, 36] Two general population-
based studies have investigated the association between PAHs exposure and serum markers of 
CVD using the National Health and Nutrition Examination Survey (NHANES), and the results 
were inconsistent.[37, 38] Data on PAHs were withdrawn (and re-released) due to 
inconsistencies in the laboratory methods used on NHANES 2001-2002 and 2003-2004 data 
cycles. In addition, neither adjustment for active smoking and SHS exposure in addition to 
confounders known to interact with the outcomes nor stratifying by major characteristics of the 
study population was performed in those studies.  The re-release of the data provides an 
important opportunity for updated analysis. 
 The overall aim of this study was to investigate the independent association between 
urinary levels of PAH biomarkers, including 1-hydroxynapthol, 2- hydroxynapthol, 2-
hydroxyfluorene, 3-hrdroxyfluorene, 1-hydroxyphenanthrene, 2- hydroxyphenanthrene, 3-
hydroxyphenanthrene and 1-hydroxypyrene, and markers of systemic inflammation, diabetes 
mellitus and CVD, among adult participants of NHANES, a large, multiethnic, population-based, 
study representative of the general population of the United States adults (US). Since exposure to 
active smoking and SHS are major sources of PAHs, we sought to determine if this relationship 
was independent of serum cotinine, self-reported smoking status, in addition to the other 
potential confounders. 
Due to the multiple sources of PAHs in the environment, exposure to a single PAH 
compound is implausible. Metabolism, and consequently health effects of exposure to multiple 
PAHs were found to be different from that of exposure to an individual PAH compound.[39] 
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Enzyme competition was evident in the metabolism of PAH mixtures, changing significantly the 
metabolism patterns from that of individual PAHs.[39]  Therefore in the current study, and 
similar to analytical strategies employed by previous authors [40], we created a summed variable 
as a measure of cumulative exposure to multiple low molecular weight PAHs simultaneously. 
 
The specific aims of the current study were as follows:  
1. To examine the independent association of urinary PAH biomarkers and serum markers 
of systematic inflammation such as high sensitivity C-reactive protein and white blood 
cell count. 
2. To examine the independent association of urinary PAH biomarkers and diabetes 
mellitus. 
3. To examine the independent association of urinary PAH biomarkers and self-reported 
cardiovascular disease. 
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CHAPTER 1 
The Association of Urinary Levels of Polycyclic Aromatic Hydrocarbon Biomarkers and 
Serum Inflammatory Makers. 
 
Abstract  
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants, occurring 
from both anthropogenic and natural sources. Several animal studies have reported a positive 
association of PAHs with inflammation. However, it is not clear if lower background exposure to 
PAHs in the general population is associated with systemic inflammation in humans. We 
examined participants from the National Health and Nutrition Examination Survey 2001-2002, 
2003-2004, and 2005-2006. Our exposures were eight urinary monohydroxy polycyclic aromatic 
hydrocarbons (OH-PAH) and our outcomes were serum C-reactive protein (CRP) (<10 mg/L) 
and total white blood cell (WBC) count (4000-12,000 cells/µL). Compared to those with 
summed biomarkers of low-molecular weight (LMW) PAHs in the lowest quartile, the 
multivariable odds ratios (95% confidence interval) of serum CRP ≥ 3 mg/L and high total WBC 
count (defined as at or above the 95 percentile of total WBC count distribution) among those in 
the highest quartile were 1.77 (1.13, 2.76) and 1.34 (1.12, 1.60) respectively. Levels of 1-
hydroxypyrene, the biomarker of the higher molecular weight PAH pyrene, was positively 
associated with total WBC count, and to lesser extent with serum CRP. In subsequent analyses, 
the positive association between LMW PAHs and serum CRP and total WBC count was found to 
be present within the stratified subgroups. In conclusion, urinary levels of PAH biomarkers were 
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found to be positively associated with serum CRP and total WBC count independent of smoking 
and other potential confounders. 
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Systemic inflammation is considered a key risk factor for atherosclerosis and subsequent 
development of cardiovascular disease (CVD).[5] Several studies have reported a positive 
association between baseline elevations of C-reactive protein (CRP), a serum inflammatory 
maker, and future risk of CVD.[41, 42] Clinical and public health groups have recommended 
serum CRP levels to be used as a CVD risk stratifying tool.[43] In addition, elevations in total 
white blood cells (WBC) count within the normal range (4000-12,000 cells/uL) were found to be 
independently associated with increased risk of CVD and have been proposed as an alternate 
serum inflammatory marker.[44]   
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants composed of 
fused aromatic rings.[16, 21, 45] PAHs may occur in oil, coal, and tar deposits, and are produced 
as byproducts of smoking, and indoor and outdoor fuel burning.[18, 46] PAHs can be also found 
in contaminated water, and in food as a result of food processing, preparation, and cooking. [47, 
48] Further, exposure to PAHs is markedly increased by cigarette smoking. Several in-vitro and 
animal studies have reported a positive association between exposure to PAHs and systemic 
inflammation. [28, 49-51] However, it is not clear if the lower background exposure to PAHs is 
associated with inflammatory effects in humans in the general population. 
In this context, we examined the association of eight urinary biomarkers of PAHs, the 
monohydroxy-PAHs (OH-PAH), with serum CRP and total WBC count in a nationally 
representative sample of United States (US) adults. Since exposure to active smoking and second 
hand smoke are major sources of PAHs, we sought to determine if this relationship was 
independent of serum cotinine, self-reported smoking status, and other potential confounders.  
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Due to the multiple sources of PAHs in the environment, exposure to a single PAH 
compound is implausible. Metabolism, and consequently health effects of exposure to multiple 
PAHs were found to be different from that of exposure to an individual PAH compound.[39] 
Enzyme competition was evident in the metabolism of PAH mixtures, changing significantly the 
metabolism patterns from that of individual PAHs.[39]  Therefore in the current study, and 
similar to analytical strategies employed by previous authors [40], we created a summed variable 
as a measure of cumulative exposure to multiple low molecular weight PAHs simultaneously. 
 
METHODS 
Study population  
The present study is based on merged data from the 2001-2002, 2003-2004 and 2005-
2006 National Health and Nutrition Examination Survey (NHANES). Detailed description of 
NHANES study design and methods are available elsewhere.[52] NHANES included a stratified 
multistage probability sample representative of the civilian non-institutionalized US population. 
Selection was based on counties, blocks, households and individuals within households, and 
included oversampling of non-Hispanic Blacks and Mexican Americans in order to provide 
stable estimates of these groups. Out of 31,509 participants in NHANES 2001-2006, there were 
11, 512 who were 20-65 years of age. Urinary PAH biomarkers were only measured in a 
subsample of individuals. The subsample is nationally representative, but with a smaller analytic 
sample size. 
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We excluded participants with missing information on serum CRP or with CRP levels 
>10 mg/L, indicating potential underlying non-cardiovascular causes of inflammation.[53] We 
further excluded participants with missing information on serum cotinine level, or other 
covariates included in the final CRP model. Similarly, to minimize the confounding effect of 
infection, only subjects with a WBC count within the normal range (4000-12,000 cells/uL) were 
included in the final WBC analysis. We also excluded participants with missing information on 
total WBC count, or other covariates included in the final model. 
Main outcome of interest:  Serum inflammatory markers 
 High sensitivity serum C - reactive protein. 
Serum CRP was measured using latex-enhanced nephelometry. Details of the laboratory 
collection, processing, and analysis are available in the laboratory procedures manual.[54] High 
CRP level was defined as ≥3 mg/dL, consistent with American Heart Association/Centers for 
Disease Control & Prevention (AHA/CDC) guidelines for identifying subjects with high risk of 
CVD.[7] 
Total white blood cell count within normal values. 
The methods used to derive WBC count are based on the Beckman Coulter method of 
counting. High WBC count was defined as values at or above the 95
th
  percentile of the study 
population distribution, consistent with previous studies examining the association between total 
WBC count within normal ranges and CVD risk.[10, 55] 
 
Main exposure: Urinary levels of monohydroxy-PAH  
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Urine specimens collected during the clinical exam portion of the survey were processed, 
stored, and shipped to the Division of Environmental Health Laboratory Sciences, National 
Center for Environmental Health, Centers for Disease Control and Prevention for analysis. The 
specific analytes measured in this study were monohydroxy-PAH (OH-PAH). By evaluating 
these analytes in urine, a measurement of the body burden from PAH exposure is obtained.[24] 
The procedure involves enzymatic hydrolysis of urine, extraction, derivatization and analysis 
using capillary gas chromatography combined with high resolution mass spectrometry (GC-
HRMS).  Detailed specimen collection and processing instructions are discussed in the 
NHANES Laboratory/Medical Technologists Procedures Manual (LPM). 
   Seven LMW PAH urinary biomarkers, Naphthalene biomarkers; 1- hydroxynaphthalene, 
2- hydroxynaphthalene, Fluorene biomarkers; 2-hydroxyfluorene, 3-hydroxyfluorene, 
Phenanthrene biomarkers; 1-hydroxyphenanthrene, 2- hydroxyphenanthrene, 3- 
hydroxyphenanthrene and 1-hydroxypyrene, the biomarker of the higher molecular weight PAH 
pyrene, were consistently available in NHANES 2001-2006. All analytes were measured in the 
same unit; ng/L. Urinary OH-PAH were corrected for urinary creatinine concentration, a urinary 
marker of kidney function to adjust for urinary dilution.[56] Urinary levels of OH-PAH (ng/L) 
were divided by urinary creatinine level (mg/dL) multiplied by 0.01; [(ng/L) ÷ (mg/dL*0.01)] 
and expressed as nanogram per gram of creatinine (ng/g creatinine). 
 
Exposure measurements 
Information on age, gender, race/ethnicity, alcohol intake, income, diabetes and cigarette 
smoking were obtained from a standardized questionnaire during a home interview. Alcohol 
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consumption was categorized into none and alcohol drinker. Income-poverty ratio 
(Income/poverty guideline) was used as a measure of the socioeconomic status. The Department 
of Health and Human Services’ poverty guidelines were used as the poverty measure to calculate 
this ratio. Smoking status was categorized into never smokers (smoked <100 cigarettes during 
their lifetime), former smokers (smoked ⩾100 cigarettes during their lifetime and currently not 
smoking), current smokers (smoked ⩾100 cigarettes during their lifetime and currently 
smoking). Information on anthropometric, physical and laboratory components were obtained 
during the medical examination center examination. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters squared. Seated blood pressure was measured 
using a mercury sphygmomanometer according to the American Heart Association and 
recommendations.[57] Up to 3 measurements were averaged for blood pressure. 
Statistical analysis 
Urinary levels of OH-PAH were analyzed both as continuous as well as categorical 
variables. For analysis as continuous variables, urinary OH-PAH levels were log-transformed as 
a result of their skewed distribution. Weighted Pearson correlation coefficients between 
individual OH-PAH were calculated to evaluate the correlations between pairwise combinations 
of all eight urinary metabolites. We created an additive LMW PAH biomarkers variable by 
summing urinary levels of metabolites of the low molecular weight PAHs (naphthalene, fluorene 
and phenanthrene).  
We ran linear regression models to calculate the multivariable change and 95% 
confidence interval (CI) in serum CRP and total WBC count with increasing individual and 
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additive urinary OH-PAH levels. In addition, we ran logistic regression models to calculate the 
multivariable odds ratio (OR) and 95% CI of high serum CRP (≥ 3 mg/L) and total WBC count 
at or above the 95th percentile of the total WBC count distribution, for each higher urinary OH-
PAH quartile by using the lowest quartile as the referent. Variables were included in the model if 
they satisfied two conditions; first, a plausible association with the main exposure/outcome, and 
second, a > 10 percent change of odds ratio after adjusting for the potential. Accordingly, final 
models were adjusted for age (years), sex (men, women), ethnicity (non-Hispanic White, non-
Hispanic Black, all others), poverty-income ratio (%), alcohol drinking (yes/no), diabetes 
(absent/present), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine 
(ng/mL) and systolic blood pressure (mm Hg).  
To further ensure that the association is homogenous for subgroups, we performed 
subgroup analyses by gender, race/ethnicity, BMI and smoking categories. Sample weights that 
account for the unequal probabilities of selection, oversampling, and nonresponse in the 
NHANES survey were applied for all analyses. Analyses were conducted using SAS (version 
9.3, SAS Institute, Cary, NC) software. Standard errors were estimated using the Taylor series 
linearization method.   
 
RESULTS 
Table 1 presents the baseline characteristics of the study population with CRP levels<10 
mg/L. The study population was primarily non-Hispanic White (72.9%). Approximately one-half 
(50.5%) were never smokers, and the remainder were former smokers (21.7%) and current 
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smokers (27.8%). The arithmetic mean of serum cotinine level was 74.2 ng/mL. Tables 2 and 3 
present the weighted percentiles and means of individual and additive LMW urinary OH-PAH 
metabolites used in the final CRP and total WBC count analyses, respectively. 
Table 4 present the results of the analyses examining the correlations between pairwise 
combinations of all eight urinary metabolites in addition to serum cotinine. The results indicate 
that significant correlations exist between all OH-PAH pairwise combinations, with Pearson 
correlation coefficients that ranged from 0.41 to 0.93.  
Tables 5 and 6 present the results of the linear regression analyses measuring the 
association between urinary OH-PAH levels, serum CRP and total WBC count respectively. 
Urinary levels of OH-PAH were positively associated with serum CRP levels independent of 
potential confounders. All the associations were statistically significant except for 1- 
hydroxynaphthalene, 3-hydroxyphenanthrene and 1-hydroxypyrene. Similarly urinary levels of 
OH-PAH were positively associated with total WBC count independent of potential confounders.  
Table 7 presents the odds ratio of the association between urinary levels of OH- PAH and 
high CRP, defined as CRP levels ≥ 3 mg/L.  Overall, urinary levels of OH-PAH were positively 
associated with high CRP in the multivariable adjusted models. Using urinary OH-PAH levels as 
continuous variables, the observed associations were still positive. Although positive, the 
associations between urinary 3-hydroxyphenanthrene and serum CRP were not statistically 
significant. 
Table 8 presents the odds ratios of the association between urinary levels of OH-PAH and 
high WBC count (defined as at or above the 95
th
 percentile of the total WBC count distribution). 
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Similar to the results for CRP, urinary levels of OH-PAH were positively associated with high 
total WBC count in the multivariable adjusted models. Using urinary OH-PAH levels as 
continuous variables, the observed associations were still positive. Although positive, the 
associations between urinary 1-hydroxyphenanthrene and 3-hydroxyphenanthrene and total 
WBC were not statistically significant. 
Table 9 investigates several types of potential confounding. We performed subgroup 
analyses by gender, race/ethnicity, BMI and smoking categories. Overall, consistent with the 
findings for the whole cohort, we found that higher urinary levels of LMW PAHs biomarkers 
were positively associated with high CRP and high total WBC count within these stratified 
subgroups. Compared to females, urinary biomarkers of LMW PAH showed stronger 
associations with serum CRP and high total WBC count among males. Compared to non-
smokers, urinary biomarkers levels of LMW PAH showed a stronger association with high total 
WBC count among current smokers. Some of the odds ratios failed to reach the conventional 
levels of statistical significance. P-interaction values for cross-product terms between urinary 
OH-PAH levels and stratifying variables were all >0.15 except for gender in the CRP analysis 
(P=0.001) and in the WBC analysis (P=0.003).  
 
DISCUSSION 
In a multiethnic sample of US adults, we found that higher levels of urinary PAH 
biomarkers were positively associated with high serum CRP levels and total WBC count, 
independent of surveyed smoking status, serum cotinine and other potential confounders. The 
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association was stronger for the low molecular weight PAH biomarkers, compared to 1-
hydroxypyrene, a urinary metabolite of the higher molecular weight PAH pyrene.  
Researchers have examined PAHs directly in the blood and tissues of experimental 
animals, and in humans.  The most commonly used biomarkers of PAH exposure are urinary 
OH-PAH. Urinary OH-PAH has been found to correlate well with levels of exposure to PAHs in 
the general population.[24] In addition, there is an evidence that the additional effect of human 
occupational exposures can be detected, independent of cigarette smoking.[25] 
Humans are usually exposed to PAHs occurring in either a gas or particulate phase. 
PAHs with the lower molecular weight (Naphthalene, Fluorene, and Phenanthrene) are more 
abundant in the gas phase and are absorbed mainly through inhalation.[58] In contrast,  PAHs 
with higher molecular weight (Pyrene) have higher vapor pressure and are found in a particulate 
form.[58] They can be absorbed through ingestion, skin contact and inhalation.[16, 22]  
The mechanisms underlying the positive association of urinary PAH biomarkers with 
serum CRP and total WBC count remain unknown. Several in-vitro and animal studies have 
reported a positive association between exposure to PAHs and systemic inflammation. [28, 49-
51] Upon exposure to PAHs, detoxification occurs, leading to the formation of highly reactive 
intermediates that can interact with the DNA, forming PAH-DNA plaques in animal arteries. [28, 
30]  Several studies have suggested that PAHs might exert this atherogenic effect via stimulation 
of an inflammatory process involving an increased influx of proinflammatory cells into these 
plaques.[49] 
Stratifying by gender, the positive association between urinary LMW PAH biomarkers 
and serum CRP ≥3 mg/L and total WBC at or above the 95th percentile was found to be stronger 
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in males when compared to females, suggesting possible gender differences. It is possible that 
hormonal differences in the way in which men and women metabolize PAHs may explain this 
observation. PAHs are known to be metabolized by cytochrome P450.[59] It has been shown that 
women have increased lung expression of CYP enzymes compared with men which is related to 
estrogen.[60, 61] Consequently, accelerated breakdown of PAHs in the lungs may potentiate the 
pulmonary response to PAHs in females while reducing the circulating PAH concentrations.[62]  
Only two human studies have investigated the association between PAH exposure and 
serum inflammatory markers, and the results were inconsistent. In a study of 999 participants 
using NHANES 2003–2004, higher exposure to PAHs was associated with elevated levels of 
serum CRP.[37] However, in a study of participants in NHANES 2001–2004, urinary levels of 
OH-PAH were not associated with other serum inflammatory markers such as total WBC 
count.[63] The differences in the results may be partly due to the fact that some NHANES data 
on PAHs were withdrawn (and re-released) due to inconsistencies in the laboratory methods used 
in 2001-2002 and 2003-2004 data cycles. The re-release of the data provides an important 
opportunity for updated analysis.   In addition, previous studies included participants with CRP 
levels of higher than 10 and total WBC count higher than 12,000 cells/µL, where infection or 
autoimmune diseases might have confounding effects. Also adjustment for major confounders 
known to interact with inflammatory markers such as alcohol drinking, total cholesterol and 
socioeconomic status, and stratifying by major characteristics of the study population were not 
performed in these previous studies.  
The current study used merged data from NHANES 2001-2002, 2003-2004 and 2005-
2006. The strengths of the study include the relatively large multiethnic sample of the US adults, 
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the high quality of NHANES data due to standardized data collection and the ability to adjust for 
potential confounders and to stratify by major sociodemographic characteristics. In addition, we 
investigated the association of PAH exposure with serum CRP and total WBC count, 
independent of the health effects of smoking by adjusting for serum cotinine, an objective 
measure of cigarette smoke exposure in addition to stratifying by self-reported smoking status. 
Cotinine is the principal metabolite of nicotine. [64] Serum cotinine is considered a more precise 
measure of exposure to cigarette smoking when compared to self-reported smoking status, [65, 
66] and is considered an accurate biomarker of second-hand smoke exposure. [67]  
  The study has limitations as well. The cross-sectional nature of NHANES does not allow 
us to draw temporal or causal inferences regarding the relationship between PAHs and serum 
inflammatory markers. Urinary OH-PAH measurements reflect recent exposure to PAHs and do 
not reflect differences between the current exposure sources and the past exposure sources for 
each subject. Due to its short half-life, serum cotinine also reflects recent exposure to tobacco 
smoke. However, these biases are likely to be non-differential biases, which would minimize any 
associations observed.  
In conclusion, lower background exposure to PAHs was found to be positively associated 
with serum markers of systemic inflammation, i.e. serum CRP and total WBC count independent 
of potential confounders. Active smoking appears to play a significant role in the association of 
urinary OH-PAH and total WBC count, yet the association persists after adjustment for serum 
cotinine and self-reported smoking status. There is a need to replicate these findings in future 
prospective studies with adequate sample size. 
 
19 
 
 
 
Table 1. Baseline characteristics of the study population (20-65 years of age) with measured 
urinary levels of OH-PAH and CRP≤ 10mg/L 
Characteristics 
Mean values (Std error of mean) or  
Sample size (weighted percentages)  
Female (%) 1136 (47.7) 
Age (years) 40.9 (0.34) 
Race/Ethnicity (%)  
  Non-Hispanic Whites 1200 (72.9) 
  Non-Hispanic Blacks 463 (10.0) 
  Others 691 (17.1) 
Education categories (%)  
  Less than high school 547 (14.2%) 
  High school 541 (24.2) 
  Above high school 1266 (61.6) 
Below poverty level (%) 392 (12.1) 
Smoking categories (%)  
  Never  1229 (50.5) 
  Former smokers 501 (21.7) 
  Current  smokers 624 (27.8) 
Alcohol drinking (%)  
  Yes  1731 (77.2) 
Body mass index (%)  
  Normal weight (<25.0 kg/m
2
) 784 (36.5) 
  Overweight (25.0-29.9 kg/m
2
) 827 (32.9) 
  Obese (>30.0 kg/m
2
) 743 (30.6) 
Serum cotinine (ng/mL) 74.2 (4.25) 
Total cholesterol (mg/dL) 201.6 (1.43) 
Systolic blood pressure (mmHg) 119.1 (0.47) 
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Table 2: Weighted percentiles of OH-PAH (ng/g creatinine) among participants included in the final analysis with serum CRP levels ≤ 10mg/L 
Chemicals Selected percentiles 
 Sample 
size 
Mean  Minimum  10
th
  25
th
  50
th
  75
th
  90
th
   Maximum 
                  
1- Hydroxynaphthalene 2480 44914  50.8  502.6  843.7  2009.3  7116.1  17899   39226536 
2-Hydroxynaphthalene 2488 6235.5  93.5  795.9  1341.8  2820.7  7947.9  16009   404573 
                  
2-Hydroxyfluorene 2465 654.4  2.2  102.4  143.3  247.8  751.2  1756.9   29914 
3-Hydroxyfluorene 2450 339.0  1.2  34.5  52.5  97.6  407.4  1014.8   19084 
                  
1-Hydroxyphenanthrene 2469 215.31  0.7  60.8  89.3  139.7  232.7  371.3   8341.9 
2-Hydroxyphenanthrene 2448 96.6  0.5  22.3  35.1  56.9  99.9  177.1   5069.4 
3-Hydroxyphenanthrene 2444 191.5  0.7  37.7  55.4  91.8  176.2  342.0   20248 
                  
1-Hydroxypyrene 2461 136.5  0.9  22.3  35.5  66.1  136.6  272.7   10014 
                  
Summed LMW PAH biomarkers 2369 54230  620.0  2119.5  3156.6  6140.5  18777  38131   39235478 
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Table 3: Weighted percentiles of OH-PAH (ng/g creatinine) among participants included in the final analysis with total WBC count between 
4000-12,000 cells/µL 
Chemicals and blood markers Selected percentiles 
 Sample 
size 
Mean  Minimum  10
th
  25
th
  50
th
  75
th
  90
th
   Maximum 
                  
1-Hydroxynaphthalene 2620 43340  50.8  485.6  825.2  1963.4  6878.0  17816   39226536 
2-Hydroxynaphthalene 2628 6156.1  9.2  796.5  1357.5  2825.1  7829.2  15544   404573 
                  
2-Hydroxyfluorene 2604 632.8  2.2  102.8  143.4  244.4  735.1  1687.9   29914 
3-Hydroxyfluorene 2588 325.5  1.2  34.3  52.3  95.7  377.7  950.2   19084 
                  
1-Hydroxyphenanthrene 2610 213.2  0.7  60.9  89.7  140.4  229.3  366.9   8341.9 
2-Hydroxyphenanthrene 2587 96.3  0.5  22.7  35.7  58.3  101.2  177.3   5069.4 
3-Hydroxyphenanthrene 2585 189.1  0.7  37.5  54.9  90.0  170.6  331.0   20248 
                  
1-Hydroxypyrene 2600 133.9  0.9  22.5  35.4  65.4  132.0  267.3   10014 
                  
Summed LMW PAH biomarkers 2505 52480  508.7  2122.4  6085.4  18255  18255  37021   39235478 
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Table 4: Weighted Pearson correlations between log-transformed urinary levels OH-PAH (ng/g creatinine). 
Chemicals  1-NAP*  2- NAP*  2-FLUO
+
  3-FLUO
+
  1-PHENᵟ  2-PHENᵟ  3-PHENᵟ  1-PYRŷ 
                 
1- Hydroxynaphthalene  1  0.60  0.61  0.62  0.43  0.41  0.48  0.49 
2- Hydroxynaphthalene  -----  1  0.71  0.71  0.43  0.48  0.53  0.57 
                 
2-Hydroxyfluorene  -----  -----  1  0.93  0.66  0.68  0.75  0.73 
3-Hydroxyfluorene  -----  -----  -----  1  0.60  0.62  0.73  0.71 
                 
1-Hydroxyphenanthrene  -----  -----  -----  -----  1  0.76  0.78  0.72 
2-Hydroxyphenanthrene  -----  -----  -----  -----  -----  1  0.76  0.71 
3-Hydroxyphenanthrene  -----  -----  -----  -----  -----  -----  1  0.72 
                 
1-Hydroxypyrene  -----  -----  -----  -----  -----  -----  -----  1 
* NAP= Hydroxynaphthalene      + FLUO= Hydroxyfluorene        ᵟ PHEN= Hydroxyphenanthrene        ŷ PYR = Hydroxypyrene 
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Table 5: Linear regression:  Association of urinary OH-PAH levels (ng/g creatinine) and serum CRP (mg/L). 
     Chemicals  Sample size Log OH-PAH Log OH-PAH 
  Age-sex adjusted change in CRP 
+
 Multivariable change in CRP * 
1- Hydroxynaphthalene 2480 0.04(-0.03, 0.11) 0.07(-0.01, 0.14) 
2-Hydroxynaphthalene 2488 0.15(0.04, 0.26) 0.14(0.04, 0.25) 
    
2-Hydroxyfluorene 2465 0.14(0.05, 0.24) 0.16(0.06, 0.26) 
3-Hydroxyfluorene 2450 0.07(0.00, 0.14) 0.10(0.02, 0.18) 
    
1-Hydroxyphenanthrene 2469 0.20(0.07, 0.32) 0.21(0.10, 0.33) 
2-Hydroxyphenanthrene 2448 0.24(0.05, 0.43) 0.19(0.01, 0.36) 
3-Hydroxyphenanthrene 2444 0.02(-0.11, 0.15) 0.05(-0.06, 0.17) 
    
1-Hydroxypyrene 2461 0.11(0.001, 0.22) 0.11(-0.004, 0.21) 
    
Summed LMW PAH biomarkers 2369 0.13(0.02, 0.23) 0.15(0.04, 0.25) 
+ 
Adjusted for age (years) and sex (Male/ Female). 
* Adjusted for age (years), sex (Male/ Female), BMI (Normal weight/ Overweight/ Obese), race (Non-Hispanic white/ Non-Hispanic black/ all 
others), alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/ present) and 
systolic blood pressure (mm Hg). 
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Table 6: Linear regression:  Association of urinary OH-PAH levels (ng/g creatinine) and total WBC count (cells/uL). 
     Chemicals  Sample size Log OH-PAH Log OH-PAH 
  Age-sex adjusted change in WBC
+
 Multivariable change in WBC * 
1- Hydroxynaphthalene 2620 176.1(108.8, 243.4) 89.7(8.9, 170.5) 
2-Hydroxynaphthalene 2628 345.5(233.4, 457.6) 229.2(103.2, 355.3) 
    
2-Hydroxyfluorene 2604 396.2(310.8, 481.5) 310.1(190.1, 430.0) 
3-Hydroxyfluorene 2588 305.8(237.5, 347.1) 235.9(135.9, 335.9) 
    
1-Hydroxyphenanthrene 2610 206.9(110.8, 503.0) 132.4(19.5, 245.3) 
2-Hydroxyphenanthrene 2587 354.7(258.1, 451.3) 213.6(117.3, 309.9) 
3-Hydroxyphenanthrene 2585 308.0(204.3, 411.7) 199.8(81.8, 317.7) 
    
1-Hydroxypyrene 2600 283.5(201.4, 365.6) 144.5(53.8, 235.2) 
    
Summed LMW PAH biomarkers 2505 296.4(202.3, 390.44) 186.0(73.0, 299.0) 
+ 
Adjusted for age (years) and sex (Male/ Female). 
* Adjusted for age (years), sex (Male/ Female), BMI (Normal weight/ Overweight/ Obese), race (Non-Hispanic white/ Non-Hispanic black/ all 
others), alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/ present) and 
systolic blood pressure (mm Hg). 
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Table 7. Logistic regression: Association of urinary OH-PAH levels (ng/g creatinine) and CRP ≥3mg/L 
     Chemicals  Sample size Quartile 1 Quartile 2 Quartile 3 Quartile 4 Log-PAH 
          Multivariable odds ratio  (95% confidence interval)* 
   
1-Hydroxynaphthalene
 
 2480 1 (Referent) 0.94(0.69, 1.28)  1.07(0.75, 1.52) 1.53(1.01, 2.32) 1.08(0.98, 1.20) 
2-Hydroxynaphthalene  2488 1 (Referent) 1.10(0.80, 1.51)  1.22(0.81, 1.82) 1.66(1.10, 2.48) 1.15(1.01, 1.32) 
       
2-Hydroxyfluorene  2465 1 (Referent) 1.09(0.79, 1.50)  1.34(0.95, 1.89) 1.63(1.14, 2.33) 1.22(1.09, 1.37) 
3-Hydroxyfluorene  2450 1 (Referent) 0.97(0.72, 1.31)  1.17(0.87, 1.59) 1.58(1.15, 2.16) 1.14(1.03, 1.25) 
       
1-Hydroxyphenanthrene 2469 1 (Referent) 1.45(1.00, 2.12)  1.84(1.38, 2.46) 1.67(1.25, 2.22) 1.23(1.09, 1.40) 
2-Hydroxyphenanthrene
  
 2448 1 (Referent) 1.23(0.74, 2.05)  1.58(1.00, 2.51) 1.88(1.26, 2.80) 1.25(1.01, 1.54) 
3-Hydroxyphenanthrene  2444 1 (Referent) 1.01(0.71, 1.43) 1.03(0.76, 1.40) 1.21(0.90, 1.64) 1.09(0.96, 1.24) 
       
1-Hydroxypyrene
 
 2461 1 (Referent) 1.24(0.86, 1.78) 1.41(1.09, 1.81) 1.38(0.92, 1.95) 1.14(1.01, 1.29) 
       
Summed LMW PAH biomarkers 2369 1 (referent) 1.09(0.73, 1.61) 1.18(0.80, 1.75) 1.77(1.13, 2.76) 1.16(1.03, 1.31) 
*Adjusted for age (years), sex (Male/ Female), BMI (Normal weight/ Overweight/ Obese), race (Non-Hispanic white/ Non-Hispanic black/ all others), 
alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/ present) and systolic 
blood pressure (mm Hg). 
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Table 8. Logistic regression: Association of urinary OH-PAH levels (ng/g creatinine) and high total WBC count (cells/uL) at or above the 95
th
 
percentile of the total WBC distribution 
     Chemicals  Sample size Quartile 1 Quartile 2 Quartile 3 Quartile 4 Log-PAH 
 Multivariable odds ratio  (95% confidence interval)* 
  
1-Hydroxynaphthalene  2620 1 (Referent) 1.44(0.78, 2.64)  1.20(0.60, 2.39) 2.18(1.17, 4.05) 1.18(1.02, 1.37) 
2-Hydroxynaphthalene  2628 1 (Referent) 0.70(0.30, 1.59) 0.98(0.49, 1.97) 2.58(1.05, 6.35)    1.33(0.87, 2.03) 
       
2-Hydroxyfluorene  2604 1 (Referent) 1.02(0.44, 2.36)  1.63(0.86, 3.08) 3.07(1.47, 6.43) 1.50(1.17, 1.92) 
3-Hydroxyfluorene  2588 1 (Referent) 1.34(0.62, 2.89)  1.90(0.93, 3.87) 4.15(1.93, 8.92) 1.42(1.14, 1.78) 
       
1-Hydroxyphenanthrene
 
 2610 1 (Referent) 1.04(0.51, 2.13)  1.67(0.90, 3.10) 1.52(0.77, 3.02) 1.20(0.91, 1.58) 
2-Hydroxyphenanthrene
 
 2587 1 (Referent) 1.94(0.89, 4.23)  1.45(0.69, 3.04) 2.25(1.07, 4.75) 1.32(1.03, 1.70) 
3-Hydroxyphenanthrene  2585 1 (Referent) 1.55(0.85, 2.83) 1.19(0.64, 2.20) 1.86(0.92, 3.76) 1.27(0.99, 1.64) 
       
1-Hydroxypyrene  2600 1 (Referent) 1.68(0.80, 3.55)  1.94(0.98, 3.82) 2.27(1.12, 4.61) 1.31(1.03, 1.66) 
       
Summed LMW PAH 
Biomarkers 
2505 1 (Referent) 0.98(0.51, 1.90)  1.03(0.59, 1.80) 2.57(1.27, 5.19) 1.34(1.12, 1.60) 
*Adjusted for age (years), sex (Male/ Female), BMI (Normal weight/ Overweight/ Obese), race (Non-Hispanic white/ Non-Hispanic black/ all others), 
alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/ present) and systolic 
blood pressure (mm Hg). 
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Table 9. Logistic regression: Association of summed urinary biomarkers of LMW PAHs (ng/g creatinine) and serum inflammatory markers by 
sociodemographic characteristics 
Subgroups Multivariable odds ratio of CRP 
≥3mg/L* 
P interaction Multivariable odds ratio of total WBC count in 
the 95
th
 percentile* 
p-interaction 
     
Gender*  0.001  0.003 
 Female  1.08(0.93, 1.25)  1.21(0.95, 1.55)  
 Male 1.32(1.12, 1.55)  1.90(1.41, 2.56)  
     
Race-ethnicity*  0.29  0.29 
 Non-Hispanic white 1.16(1.00, 1.34)  1.34(1.10, 1.64)  
 All others 1.18(0.98, 1.41)  1.27(0.92, 1.74)  
     
Body mass index
+
  0.55  0.71 
Non obese 1.20(1.01, 1.41)  1.39(1.11, 1.75)  
Obese 1.08(0.91, 1.27)  1.28(1.00, 1.64)  
     
Smoking*  0.27  0.35 
 Never smokers 1.21(0.98, 1.50)  1.21(0.88, 1.68)  
 Former smokers 1.03(0.88, 1.19)  1.15(0.83, 1.59)  
 Current  smokers 1.10(0.81, 1.49)  1.78(1.28, 2.48)  
* Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic white, non-Hispanic black, all others), poverty-income ratio, alcohol drinking 
(yes/no), diabetes (absent/present), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure 
(mm Hg), except for stratified variables. 
+ Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic white, non-Hispanic black, all others), poverty-income ratio, alcohol drinking 
(yes/no), diabetes (absent/present), BMI (Kg/m
2
), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg), 
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CHAPTER 2 
The Association of Urinary Polycyclic Aromatic Hydrocarbon Biomarkers and Diabetes 
Mellitus. 
Abstract 
  Diabetes mellitus is a major cause of morbidity and mortality in the United States. Recent 
evidences has suggested that common environmental exposures affecting large sections of the 
population may be a determinant of diabetes risk. Polycyclic aromatic hydrocarbons (PAHs) are 
a group of compounds produced as byproducts of incomplete combustion of organic materials. 
Animal studies have reported a positive association between PAHs and inflammation, and 
subsequent development of diabetes mellitus. Occupational studies have suggested that exposure 
to other aromatic hydrocarbons such as Dioxins, a group of halogenated aromatic hydrocarbons, 
may be associated with diabetes mellitus risk in humans.  In the current study we investigate 
whether background exposure to PAHs is associated with increased risk of diabetes mellitus in 
the general population. We examined participants from the merged National Health and 
Nutrition Examination Survey 2001-02, 2003-2004, and 2005-2006. Our exposures of interest 
were eight urinary monohydroxy polycyclic aromatic hydrocarbons (OH-PAH) and our outcome 
was diabetes mellitus defined as a serum glucose ≥126mg/dL after fasting for a minimum of 8 
hours, glycosylated hemoglobin level ≥ 6.5%, a self-reported physician-diagnosed diabetes, or 
current use of oral hypoglycemic medication or insulin. Compared to participants with summed 
urinary  biomarkers of LMW PAHs in the lowest quartile, the multivariable odds ratio (95% 
confidence interval) of  diabetes mellitus among those in the highest quartile was 2.79 (1.46, 
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5.32). In addition, urinary levels of 2-hydroxynapthalene, 2-hyrdroxyfluorene, and 2-
hydroxyphenanthrene showed statistically significant associations with fasting blood glucose 
(mg/dl) and glycosylated hemoglobin (%), independent of potential confounders. Levels of 1-
hydroxypyrene, the urinary biomarker of the higher molecular weight PAH pyrene, showed a 
less strong association with diabetes mellitus.
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Diabetes mellitus is the seventh leading cause of death in the US.[30] Approximately 
8.3% of the American population has diabetes.[30] Diabetes is a major risk factor for 
cardiovascular disease, kidney failure, non-traumatic lower limb amputations, and retinopathy 
among adults in the US.[2, 3] Recent studies have suggested that common environmental 
exposures affecting large sections of the population may be a determinant of diabetes risk.[13] 
Polycyclic aromatic hydrocarbons (PAHs) are a group of atmospheric pollutants 
composed of aromatic rings.[16, 21, 45] Major sources of PAHs include coal, oil, tar, cigarette 
smoking and grilled/smoked food.[47, 48, 68] PAHs are usually found in gaseous or particulate 
form. Low molecular weight (LMW) PAHs (naphthalene, Fluorene and Phenanthrene) are 
usually found in gaseous form in the ambient air where they are absorbed by inhalation. Higher 
molecular weight PAHs (pyrene) are usually found in particulate form where they can be 
ingested, inhaled or absorbed through the skin.[22, 69]  
Several in-vitro and animal studies have reported a positive association between exposure 
to PAHs, and inflammation with subsequent development of diabetes mellitus.[70] In addition, 
several studies have suggested that exposure to other aromatic hydrocarbons such as Dioxins, a 
group of halogenated aromatic hydrocarbons is associated with diabetes mellitus in humans.[14] 
However, there are no studies investigating the association of lower background exposure to 
PAHs with diabetes mellitus in the general population independent of smoking, a major source 
of PAHs. 
 In this context, we examined the association between eight urinary monohydroxy-PAH 
(OH-PAH) and diabetes mellitus in a nationally representative sample of United States (US) 
adults after adjusting for age, gender, race/ethnicity, body mass index(BMI), serum cotinine, 
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self-reported smoking status and other potential confounders. Because metabolism and health 
effects of exposure to PAHs mixtures were found to be different from that of exposure to 
individual PAHs [39] , we created a summed LMW PAH biomarker variable, indicating a 
graduating level of exposure to multiple LMW PAHs simultaneously. 
 
METHODS 
 
Study population  
The present study is based on merged data from the 2001-2002, 2003-2004 and 2005-2006 
National Health and Nutrition Examination Survey (NHANES). NHANES surveys were 
designed to be nationally representative of the non-institutionalized U.S. civilian population by 
using a complex stratified multistage probability sample.[71] Selection was based on counties, 
blocks, households and individuals within households, and included oversampling of non-
Hispanic Blacks and Mexican Americans in order to provide stable estimates of these groups. 
Data were collected from interviews, questionnaire, examinations, and laboratory tests of 
biological samples. The data have been released for public use in two-year increments since 
1999. 
Out of 31,509 participants in NHANES 2001-2006, there were 3326 participants, 20-65 years 
of age with measured levels of urinary PAH biomarkers. We excluded participants with missing 
information on serum cotinine level or other variables included in the multivariable model. This 
resulted in 2661 participants included in the additive LMW PAH-diabetes analyses. We excluded 
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those on oral hypoglycemic medications or insulin to avoid the confounding effect of 
antidiabetic medications, resulting in 2583 participants included in the added PAH biomarkers-
HbA1c analysis and 1275 participants included in the added PAH biomarkers- fasting blood 
glucose analyses 
Main outcome of interest:  Diabetes mellitus 
 
Plasma glucose concentration was determined by a hexokinase method. One-half of the 
NHANES participants were sampled to attend the morning session. Those participants ages 12 
and older appointed to attend the morning session were instructed to fast at least 9 hours prior to 
their appointment time. Glycohemoglobin measurements for NHANES 2001-2002 and 2003-
2004 were performed by the Diabetes Diagnostic Laboratory at the University of Missouri-
Columbia using Primus CLC330 and Primus CLC 385 (Primus Corporation, Kansas City, MO). 
Glycohemoglobin measurements for NHANES 2005-2006 were performed by the Diabetes 
Laboratory at the University of Minnesota using Tosoh A1c 2.2 Plus Glycohemoglobin Analyzer 
(Tosoh Medics, Inc., San Francisco, CA). Both assays use a High Performance Liquid 
Chromatography (HPLC) system. 
Diabetes was defined based on the guidelines of the American Diabetes Association as a 
serum glucose ≥126mg/dL after fasting for a minimum of 8 hours, glycosylated hemoglobin 
level ≥ 6.5% a self-reported physician-diagnosed diabetes, or current use of oral hypoglycemic 
medication or insulin.[72] 
Main exposure: Urinary levels of monohydroxy-PAH  
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Urine specimens are processed, stored, and shipped to the Division of Environmental 
Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease 
Control and Prevention for analysis. The specific analytes measured in this method are 
monohydroxy-PAH (OH-PAH). By evaluating these analytes in urine, a measurement of the 
body burden from PAH exposure is obtained. The procedure involves enzymatic hydrolysis of 
urine, extraction, derivatization and analysis using capillary gas chromatography combined with 
high resolution mass spectrometry (GC-HRMS).  Detailed specimen collection and processing 
instructions are discussed in the NHANES Laboratory/Medical Technologists Procedures 
Manual (LPM). 
  Eight urinary OH-PAH analytes, 1- hydroxynaphthalene, 2- hydroxynaphthalene, 2-
hydroxyfluorene, 3-hrdroxyfluorene, 1-hydroxyphenanthrene, 2- hydroxyphenanthrene, 3- 
hydroxyphenanthrene and 1-hydroxypyrene, are consistently available in NHANES 2001-2006. 
All analytes were measured in the same unit, ng/L. Urinary OH-PAH were corrected for 
creatinine concentration, a urinary marker of kidney function to adjust for urinary dilution [56]. 
Urinary levels of OH-PAH (ng/L) were divided by urinary creatinine level (mg/dL) multiplied 
by 0.01 i.e.; [(ng/L) ÷ (mg/dL*0.01)], and expressed as nanogram per gram of creatinine (ng/g 
creatinine). 
Exposure measurements 
Information on age, gender, race/ethnicity, alcohol intake, income and cigarette smoking 
were obtained from a standardized questionnaire during a home interview. Alcohol consumption 
was categorized into none and alcohol drinker. Income-poverty ratio was used as a measure of 
the socioeconomic status. The Department of Health and Human Services’ poverty guidelines 
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were used as the poverty measure to calculate this ratio. Smoking status was categorized into 
never smokers (smoked <100 cigarettes during their lifetime), former smokers (smoked ⩾100 
cigarettes during their lifetime and currently not smoking), current smokers (smoked ⩾100 
cigarettes during their lifetime and currently smoking). Information on anthropometric, physical 
and laboratory components were obtained during the medical examination center examination. 
Body mass index was calculated as weight in kilograms divided by height in meters squared. 
Seated blood pressure was measured using a mercury sphygmomanometer according to the 
American Heart Association and JNC7 recommendations.[57] Up to 3 measurements were 
averaged for blood pressure. Total cholesterol was measured enzymatically. Serum cotinine was 
measured by isotope dilution-high performance liquid chromatography atmospheric pressure 
chemical ionization tandem mass spectrometry (ID HPLC-APCI MS/MS). 
Statistical analysis 
Urinary levels of OH-PAH were analyzed both as continuous as well as categorical 
variables. For analysis as continuous variables, urinary levels of OH-PAH were log-transformed 
as a result of their skewed distribution. We created a summed LMW PAH variable by adding the 
urinary levels of the LMW PAHs (naphthalene, fluorene and phenanthrene). 
We ran linear regression models to calculate the multivariable change and 95% 
confidence interval (CI) in HbA1c (%) and fasting plasma glucose (mg/dl) for increasing urinary 
OH-PAH levels. In addition, we ran logistic regression models to calculate the multivariable 
odds ratio (OR) and 95% confidence interval (CI) of diabetes mellitus, for each higher urinary 
OH-PAH quartile by using the lowest quartile as the referent. Variables were included in the 
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model if they satisfied two conditions: first, a plausible association with the main outcome that is 
not causal, and second, if the percent change of the odds ratio after adjusting for the potential 
confounder was over 10 %. Accordingly, final models were adjusted for age (years), sex (men, 
women), ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty-income ratio, 
alcohol drinking (yes/no), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum 
cotinine (ng/mL) and systolic blood pressure (mm Hg).  
To further ensure that the association was parallel for subgroups, we performed subgroup 
analyses by gender, race/ethnicity, BMI and smoking categories. Sample weights that account 
for the unequal probabilities of selection, oversampling, and nonresponse in the NHANES 
survey were applied for all analyses. Analyses were conducted using SAS (version 9.3, SAS 
Institute, Cary, NC) software. Standard errors were estimated using the Taylor series 
linearization method. 
 
RESULTS 
Table 1 presents the baseline characteristics of the study population. The study 
population was primarily non-Hispanic White (72.2%). Normal weight, overweight, and obese 
BMI categories were equally distributed. Approximately one-half (50.5%) were never smokers, 
and the remainder was former smokers (21.5%) and current smokers (26.0%). The mean of 
serum cotinine level was 74.4 ng/mL. Diabetes was reported in 7.8 % of the population. Table 2 
presents the sample sizes, weighted means and weighted percentile of urinary levels of OH-PAH 
used in the final analysis. 
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Table 3 presents the results of the analyses examining the linear association between 
urinary OH-PAH, and HbA1c (%). Urinary levels of OH-PAH were positively associated with 
HbA1c levels in the multivariable adjusted model; however, 1- hydroxynaphthalene, 1-
hydroxypyrene and summed LMW PAH biomarkers were not statistically significant. Table 4 
presents the results of the analyses examining the linear association between urinary OH-PAH 
and fasting plasma glucose (mg/dl). Urinary levels of OH-PAH were positively associated with 
fasting blood glucose; however, only 2-hydroxynapthalene, 2-hrdroxyfluorene, 2-
hydroxyphenanthrene and 1-hydroxypyene were statistically significant. 
Table 5 presents the odds ratio of the association between urinary levels of OH- PAH and 
diabetes mellitus. Overall, urinary levels of OH-PAH were positively associated with diabetes 
mellitus in the multivariable adjusted models. Using urinary OH-PAH levels as continuous 
variables, the observed associations were still positive. Although positive, the associations 
between urinary 1-hydroxyphenanthrene and 1-hydroxypyrene and diabetes were not statistically 
significant. 
Next, to examine confounding, we performed subgroup analyses by gender, 
race/ethnicity, BMI and smoking categories (Table 6). Overall, higher summed levels of LMW 
PAH biomarkers were positively associated with diabetes within the stratified subgroups. 
Although positive, some of the odds ratio failed to reach the statistical significance. P-interaction 
values for cross-product terms between urinary OH-PAH levels and stratifying variables were all 
>0.10 except for BMI (P=0.03). Urinary 1-hydroxypyrene levels showed a less strong 
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association with diabetes mellitus within the stratified subgroups when compared to LMW 
PAHs. 
DISCUSSION 
In a relatively large multiethnic sample of US adults, we found that higher levels of 
urinary biomarkers of LMW PAHs were positively associated diabetes mellitus, independent of 
potential confounders. In addition, urinary levels of 2-hydroxynapthalene, 2-hrdroxyfluorene, 
and 2-hydroxyphenanthrene showed positive associations with glycosylated hemoglobin and 
fasting plasma glucose in the multivariable adjusted model. In subsequent subgroup analyses, the 
positive association was present within subgroups of gender, race, BMI and smoking status. 
Urinary biomarker levels of the higher molecular weight pyrene showed a less strong association 
with diabetes mellitus. Since LMW PAHs are usually found in gaseous form, absorption of 
PAHs through inhalation from the ambient air may exert the greatest effect on the association 
between PAHs and diabetes when compared to the higher molecular weight PAHs. 
Researchers have examined PAHs directly in the blood and tissues of experimental 
animals; however, these methods have not been widely used in humans due to the high costs and 
the limited clinical significance of testing. The most commonly used biomarkers of PAH 
exposure are urinary OH-PAH biomarkers and PAH-DNA adducts. Urinary OH-PAH 
biomarkers and, to a lesser extent, PAH-DNA adducts have been found to correlate well with 
low background levels of exposure to PAHs.[24] 
The mechanisms underlying the positive association between urinary PAH biomarkers 
and diabetes remain unknown. Several in-vitro and animal studies have reported a positive 
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association between exposure to PAHs and subsequent development of oxidative stress.[28] 
Increasing evidence suggests that oxidative stress plays a major role in the pathogenesis of 
diabetes mellitus.[73] Animal studies have reported a positive association between PAH 
exposure and inflammation.[49] In addition, higher exposure to PAHs was associated with 
elevated levels of C-reactive protein, a serum inflammatory marker in humans.[37] Inflammation 
has been found to strongly associate with insulin resistance and diabetes mellitus.[74, 75] 
Moreover, chronic exposure to PAHs was found to cause intestinal inflammation with 
subsequent increase in the risk of type 2 diabetes in animals.[70] Besides its suggested 
inflammatory effects, several studies suggested that PAHs may cause disruption of the endocrine 
system, with changes in plasma estrogen concentrations in rats upon exposure to PAHs.[32] 
Exposure to PAHs was suggested as a predisposing factor in the etiology of breast cancer by 
disrupting the expression of BRCA-1 transcription in estrogen receptor-positive tumors.[76] In 
the same context, women with a BRCA-1 mutation were found to have a 2-fold increase in the 
risk of developing diabetes.[77] 
The current study has strengths including the relatively large multiethnic sample of US 
adults, the high quality of NHANES laboratory and data collection methods and the ability to 
adjust for potential confounders. In addition, this is the first study to investigate the association 
between PAHs and diabetes in humans adjusting for potential confounders including serum 
cotinine, an objective measure of cigarette smoke exposure. Serum cotinine is considered a more 
precise measure of exposure to cigarette smoking when compared to self-reported smoking 
status[65, 66] and is considered an accurate biomarker of SHS exposure.[67]  
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The study has several limitations. The cross-sectional nature of NHANES does not allow 
us to draw temporal or causal inferences regarding the relationship between PAHs and diabetes 
mellitus. Urinary PAH measurements reflect recent exposure if there are great differences 
between the current exposure sources and the past exposure sources for each subject. However, 
these biases are likely to be non-differential biases, which would minimize any associations 
observed. In addition, because NHANES does not collect information to identify the type of 
diabetes, we cannot not distinguish type 1 and type 2 diabetes. However, we believe that the 
majority of diabetes subjects in our sample have type 2 diabetes mellitus. 
In conclusion, urinary biomarker levels of LMW PAHs were found to be positively 
associated with diabetes mellitus, independent of potential confounders. Both PAH exposure and 
diabetes mellitus are highly prevalent in the United States. Considering the limitations of our 
study, further prospective studies are necessary to determine the causal relationship between 
PAH exposure and the risk of diabetes mellitus.  
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Table 1. Baseline characteristics of the study population 20-65 years of age with measured 
urinary levels of OH-PAH (n=2661) 
Characteristics 
Mean values ± (Std error of mean) or  
Sample size (weighted percentages)  
Female (%) 1354 (49.6) 
Age (years) 41.0 ± (0.32) 
Race/Ethnicity (%)  
  Non-Hispanic Whites 1332 (72.2) 
  Non-Hispanic Blacks 551 (10.6) 
  Others 778 (17.3) 
Education categories (%)  
  Less than high school 637 (14.4) 
  High school 619 (24.7) 
  Above high school 1405 (60.9) 
Below poverty level (%) 461 (12.6) 
Smoking categories (%)  
  Never  1395 (50.5) 
  Former smokers 559 (21.5) 
  Current  smokers 707 (26.0) 
Alcohol drinking (%)  
  No   742 (23.7) 
  Yes  1919 (76.3) 
Body mass index (%)  
  Normal weight (<25.0 kg/m
2
) 824 (34.3) 
  Overweight (25.0-29.9 kg/m
2
) 901 (31.8) 
  Obese (>3vSZ0.0 kg/m
2
) 936 (33.9) 
Serum cotinine (ng/mL) 74.4 ± (3.84) 
Total cholesterol (mg/dL) 201.3 ± (1.33) 
Systolic blood pressure (mmHg) 119.3± (0.47) 
Diabetes (%) 254(7.8) 
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Table 2: Weighted percentiles of OH-PAH (ng/g creatinine) among participants included in the final analysis  
Chemicals Selected percentiles 
 Sample 
size 
Mean  Minimum  10
th
  25
th
  50
th
  75
th
  90
th
   Maximum 
                  
1- Hydroxynaphthalene 2785 41708  50.8  488.7  832.6  1996.3  7120.0  17952   39226536 
2-Hydroxynaphthalene 2794 6263.3  9.2  798.4  1356.5  2885.2  7952.5  16001   404573 
                  
2-Hydroxyfluorene 2767 651.3  2.2  102.8  144.0  245.6  752.1  1740.4   29914 
3-Hydroxyfluorene 2751 334.5  1.2  34.4  52.3  96.7  400.7  1004.8   19084 
                  
1-Hydroxyphenanthrene 2773 214.1  0.7  60.8  89.4  140.9  234.6  370.2   8341.9 
2-Hydroxyphenanthrene 2747 96.6  0.5  22.7  35.7  58.4  101.7  178.4   5069.4 
3-Hydroxyphenanthrene 2745 188.5  0.7  37.6  55.0  90.7  173.8  333.7   20248 
                  
1-Hydroxypyrene 2764 134.4  0.9  22.5  35.8  65.9  136.6  270.4   10014 
                  
Summed LMW PAH biomarkers 2661 50970  508.8  2131.3  3180.1  6207.5  18772  38592   39235478 
42 
 
 
Table 3 Linear regression: Association of urinary OH-PAH (ng/g creatinine) and HbA1c (%) 
     Chemicals  Sample size Age-sex adjusted change (95% C.I) 
in HbA1c+ 
Multivariable adjusted change (95% C.I) 
in HbA1c* 
    
1-Hydroxynaphthalene 2707 -0.01(-0.03, 0.01) 0.01(-0.01, 0.03) 
2-Hydroxynaphthalene 2715 0.02(-0.003, 0.40) 0.03(0.004, 0.06) 
    
2-Hydroxyfluorene 2688 0.01(-0.01, 0.04) 0.05(0.02, 0.09) 
3-Hydroxyfluorene 2672 0.004(-0.01, 0.03) 0.04(0.01, 0.07) 
    
1-Hydroxyphenanthrene 2694 0.02(-0.03, 0.06) 0.05(0.002, 0.10) 
2-Hydroxyphenanthrene 2668 0.05(0.02, 0.08) 0.06(0.02, 0.10) 
3-Hydroxyphenanthrene 2643 0.02(-0.01, 0.05) 0.05(0.01, 0.09) 
    
1-Hydroxypyrene 2685 0.01(-0.02, 0.04) 0.03(-0.01, 0.06) 
    
Summed LMW PAH biomarkers 2583 0.00(-0.02, 0.02) 0.01(-0.01, 0.04) 
*Adjusted for age (years), sex (male, female), race/ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty income ratio, alcohol 
drinking (yes/no), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg). 
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Table 4 Linear regression: Association of urinary OH-PAH (ng/g creatinine) and fasting glucose levels (mg/dL) 
     Chemicals  Sample size Age-sex adjusted change (95% C.I) in 
fasting glucose+ 
Multivariable adjusted change (95% C.I) in 
fasting glucose* 
    
1-Hydroxynaphthalene 1339 -0.08(-0.92, 0.77) 0.50(-0.66, 1.65) 
2-Hydroxynaphthalene 1342 1.11(0.10, 2.11) 1.95(0.26, 3.63) 
    
2-Hydroxyfluorene 1325 0.87(-0.45, 2.19) 2.50(0.28, 4.72) 
3-Hydroxyfluorene 1316 0.29(-0.83, 1.41) 1.75(-0.16, 3.65) 
    
1-Hydroxyphenanthrene 1326 2.14(-0.57, 4.84) 2.88(-0.11, 5.87) 
2-Hydroxyphenanthrene 1317 2.49(0.50, 4.47) 2.82(0.53, 5.11) 
3-Hydroxyphenanthrene 1314 0.95(-0.94, 2.83) 2.15(-0.29, 4.59) 
    
1-Hydroxypyrene 1322 1.34(-0.36, 3.04) 2.15(0.01, 4.30) 
    
Summed LMW PAH biomarkers 1275 0.27(-0.82, 1.36) 1.16(-0.50, 2.83) 
*Adjusted for age (years), sex (male, female), race/ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty income ratio, alcohol 
drinking (yes/no), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg). 
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Table 5: Logistic regression: Association of urinary OH-PAH (ng/g creatinine) and diabetes mellitus 
     Chemicals  Sample 
size 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-
Trend 
Log-PAH 
          Multivariable odds ratio  (95% confidence interval)* 
        
1- Hydroxynaphthalene  2785 1 (Referent) 1.40(0.80, 1.05)  1.65(0.99, 2.75) 3.04(1.50, 6.17) 0.003 1.19(1.02, 1.39) 
2-Hydroxynaphthalene  2794 1 (Referent) 2.70(1.55, 4.69)  1.85(1.05, 3.24) 3.25(1.75, 6.04) 0.002 1.40(1.14, 1.72) 
        
2-Hydroxyfluorene  2767 1 (Referent) 0.71(0.43, 1.17)  1.03(0.64, 1.67) 1.37(0.81, 2.31) 0.13 1.22(1.02, 1.47) 
3-Hydroxyfluorene  2751 1 (Referent) 0.77(0.47, 1.26)  1.09(0.71, 1.70) 1.49(0.84, 2.66) 0.09 1.08(0.92, 1.26) 
        
1-Hydroxyphenanthrene 2773 1 (Referent) 1.39(0.83, 2.33) 1.25(0.69, 2.25) 1.43(0.86, 2.37) 0.24 1.14(0.93, 1.41) 
2-Hydroxyphenanthrene
  
 2747 1 (Referent) 1.00(0.60, 1.68)  1.26(0.82, 1.94) 1.87(1.13, 3.10) 0.005 1.26(1.06, 1.51) 
3-Hydroxyphenanthrene  2745 1 (Referent) 1.00(0.65, 1.52) 1.27(0.84, 1.91) 1.28(0.85, 1.94) 0.12 1.21(1.01, 1.44) 
        
1-Hydroxypyrene
 
 2764 1 (Referent) 1.53(0.85, 2.72) 1.83(0.99, 3.39) 1.68(1.00, 2.83) 0.03 1.14(0.96, 1.35) 
        
Summed LMW PAH 
biomarkers 
2661 1 (referent) 1.67(0.97, 2.90) 1.91(1.19, 3.07) 2.79(1.46, 5.32) 0.002 1.26(1.02, 1.56) 
*Adjusted for age (years), sex (male, female), BMI (normal weight, overweight, obese), race (non-Hispanic White, non-Hispanic Black, all others), 
alcohol drinking (yes/ no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg). 
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Table 6. Logistic regression: Association of urinary OH-PAH (ng/g creatinine) and diabetes mellitus by sociodemographic characteristics 
Subgroups Summed urinary levels LMW PAH biomarkers 1-hydroxypyrene 
 
 
 
Multivariable odds ratio of diabetes 
mellitus 
p-interaction Multivariable odds ratio of diabetes 
mellitus 
p-interaction  
Gender*  0.51  0.27  
 Female  1.22(0.92, 1.62)  0.97(0.73, 1.27)   
 Male 1.38(1.07, 1.78)  1.26(1.002, 1.58)   
      
Race-ethnicity*  0.97  0.45  
 Non-Hispanic White 1.27(1.00, 1.63)  1.13(0.91, 1.40)   
 All others 1.19(0.90, 1.56)  1.18(0.94, 1.48)   
      
Body mass index
+
  0.03  0.19  
Non Obese 1.18(0.85, 1.64)  1.20(0.98, 1.48)   
Obese 1.26(0.96, 1.66)  1.05(0.81, 1.37)   
      
Smoking*  0.73  0.33  
 Never smokers 1.26(1.01, 1.56)  0.99(0.77, 1.28)   
 Former smokers 1.14(0.88, 1.49)  1.32(1.00, 1.75)   
 Current  smokers 1.63(0.96, 2.79)  1.36(0.93, 1.99)   
* Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty-income ratio, alcohol 
drinking (yes/no), BMI (normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg), 
except for stratified variables. 
+ 
Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty-income ratio, alcohol 
drinking (yes/no), BMI (Kg/m
2
), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood pressure (mm Hg), except for stratified 
variables. 
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CHAPTER 3 
The Association of Urinary Polycyclic Aromatic Hydrocarbon Biomarkers and 
Cardiovascular Disease. 
 
Abstract  
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants produced by 
incomplete combustion of organic materials. Several animal studies have reported a positive 
association of PAHs with oxidative stress, inflammation and subsequent development of 
atherosclerosis, a major underlying risk factor for cardiovascular disease (CVD). In addition, 
several occupational studies have reported positive associations between PAH exposure and 
CVD morbidity and mortality. However, it is not clear if lower background exposure to PAHs in 
the general population is associated with CVD. We examined participants from the merged 
National Health and Nutrition Examination Survey 2001-02, 2003-2004, and 2005-2006. Our 
exposures of interest were eight urinary monohydroxy polycyclic aromatic hydrocarbons (OH-
PAH) and our outcomes were self-reported CVD. Urinary levels of PAH biomarkers were 
positively associated with CVD, however only 1-hydroxynapthalene and additive biomarkers of 
low molecular weight (LMW) PAHs were statistically significant. Compared to those with 
summed urinary biomarkers of LMW PAHs in the lowest quartile, the multivariable odds ratio 
(95% confidence interval) of self-reported CVD among those in the highest quartile was 
2.27(1.03, 5.02). Levels of 1-hydroxypyrene, the urinary biomarker of the higher molecular 
weight PAH pyrene, also showed a significant positive association with CVD. In subsequent 
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subgroup analyses, the positive association was found to be present in subgroups of gender, 
race/ethnicity, body mass index and smoking status. This study suggested that background 
exposure to PAHs was positively associated with self-reported CVD in the U.S. general 
population. Further prospective studies with adequate sample size are needed to replicate or 
refute our findings.
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Despite advances in prevention, diagnosis and treatment, cardiovascular disease (CVD) 
remains the number one cause of mortality in United States adults.[1] From a public health point 
of view, identifying novel risk factors for CVD is therefore important. Recent epidemiological 
evidence suggests that exposure to particulate matter present in ambient air is associated with 
increased CVD risk.[78, 79] In addition, there is increasing evidence that smaller particles and 
gases may pose a greater CVD risk possibly through development of atherosclerosis.[80] 
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants that occur in 
oil, coal, and tar deposits, and are produced as byproducts of smoking, indoors and outdoors fuel 
burning and food grilling.[18, 46-48] Active smoking and second-hand smoke (SHS) exposure 
are major sources of PAHs.  PAHs are predominantly found in gaseous or particulate form. Low 
molecular weight (LMW) PAHs are abundant in gaseous form in the ambient air and are usually 
absorbed into the human body through inhalation. The higher molecular weight PAHs are 
usually found in particulate form and therefore, can be ingested, inhaled or absorbed through the 
skin.[22, 69]  
Several animal studies have reported a positive association between exposure to PAHs, 
oxidative stress, inflammation and development of atherosclerosis[28, 30, 50, 51], a major 
underlying risk factor for CVD.[81-83] In addition, occupational studies have reported positive 
associations between exposure to PAHs and CVD morbidity and mortality.[33-36] Only one 
general population based study has investigated the association between PAH exposure and 
CVD, reporting a positive association between PAHs exposure and CVD; however adjustment 
for major confounders known to interact with CVD such as diabetes mellitus and cholesterol 
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levels and stratification by major characteristics of the study population were not reported in this 
paper. [84]  
In this context, using a nationally representative sample of United States (US) adults, we 
examined the association of eight urinary biomarkers of PAHs; specifically, monohydroxy-PAH 
(OH-PAH) and self-reported CVD, independent of serum cotinine, and other potential 
confounders. Since exposure to active smoking and SHS are major sources of PAHs, we sought 
to determine if this relationship was independent of serum cotinine, self-reported smoking status, 
and other potential confounders. Because metabolism and health effects of exposure to PAHs 
mixtures were found to be different from that of exposure to individual PAHs [39] , we 
additionally created a summed LMW PAH biomarker variable, indicating a graduating level of 
exposure to multiple LMW PAHs simultaneously. 
 
METHODS 
Study population 
The National Health and Nutrition Examination Survey (NHANES) consists of a series of 
surveys designed by the National Center for Health Statistics (NCHS) to continuously monitor 
the health status of the U.S. civilian non-institutionalized US population.  The NHANES survey 
includes a stratified multistage probability sample. Selection is based on counties, blocks, 
households and individuals within households, and included oversampling of non-Hispanic 
Blacks and Mexican Americans in order to provide stable estimates of these groups. After all 
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data are collected for a two-year survey cycle, data files are made available for analysis via the 
NHANES website.[85, 86]  
In the current study we merged 2001-2002, 2003-3004 and 2005-2006 data cycles, where 
eight metabolites of PAHs have been consistently measured. Out of 31,509 participants in 
NHANES 2001-2006, there are 11, 512 who were 20-65 years of age. Urinary PAHs were only 
measured in a subsample of NHANES. We further excluded participants with missing 
information on serum cotinine and other covariates that were included in the final model. This 
resulted in 2661 participants in final added LMW PAH biomarkers model and 2764 participants 
in the final 1-hydroxypyrene model. 
 
Outcome: Self-reported cardiovascular disease 
 The participant was considered as being a prevalent CVD case if she/he answered “yes” 
to any of the following questions: ”Has a doctor or other health professional ever told you that 
you have: angina pectoris/ coronary heart disease/ heart attack/ stroke?” (These were 4 separate 
questions with the same wording style). 
 
Main exposure: Urinary levels of OH-PAH 
 Urine specimens were processed, stored, and shipped to the Division of Environmental 
Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease 
Control and Prevention for analysis. Detailed specimen collection and processing instructions are 
discussed in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM) [87]. 
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Vials are stored under appropriate frozen (–20°C) conditions until they are shipped to the 
National Center for Environmental Health for testing.  
Specific analytes measured in NHANES are monohydroxy-PAH (OH-PAH). The 
procedure involves enzymatic hydrolysis of urine, with extraction, derivatization and analysis 
using capillary gas chromatography combined with high resolution mass spectrometry (GC-
HRMS). This method uses isotope dilution with carbon-13 labeled internal standards. Ions from 
each analyte and each carbon-13 labeled internal standard are monitored, and the abundance of 
each ion is measured. The ratios of these ions are used as criteria for evaluating the data. By 
evaluating these analytes in urine, a measurement of the body burden from PAH exposure is 
obtained. 
Seven urinary LMW PAH analytes, 1-hydroxynapthol, 2- hydroxynapthol, 2-
hydroxyfluorene, 3-hyrdroxyfluorene, 1-hydroxyphenanthrene, 2- hydroxyphenanthrene, 3- 
hydroxyphenanthrene and one urinary high molecular weight analyte, 1-hydroxypyrene, were 
consistently available in NHANES 2001-2006. All analytes were measured in the same unit, 
ng/L. Urinary metabolites of PAHs were corrected for creatinine concentration, a urinary marker 
of kidney function.[88] Urinary levels of OH-PAH (ng/L) were divided by urinary creatinine 
level (mg/dL) multiplied by 0.01, i.e., [(ng/L) ÷ (mg/dL*0.01)] and expressed as nanogram per 
gram of creatinine (ng/g creatinine). 
 
Exposure variables 
In NHANES, information on age, gender, race/ethnicity, alcohol intake, income, and 
cigarette smoking were obtained during a standardized questionnaire during a home interview. 
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Information on anthropometric, physical and laboratory components were obtained during the 
medical examination center (MEC) examination. Body mass index was calculated as weight in 
kilograms divided by height in meters squared. Serum total cholesterol was measured 
enzymatically. Seated systolic and diastolic blood pressures were measured using a mercury 
sphygmomanometer according to the American Heart Association and JNC7 
recommendations.[89] Serum cotinine was measured by an isotope dilution-high performance 
liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry (ID 
HPLC-APCI MS/MS).[87] 
Statistical analysis 
Exploratory data analysis techniques were used to assess the presence of any outliers, and 
the distribution of all continuous variables was examined. For analysis as continuous variables, 
urinary OH-PAH levels were log-transformed as a result of their skewed distribution. We created 
a summed low molecular weight PAH biomarker variable by adding the urinary levels of the 
metabolites of low molecular weight PAHs (Naphthalene, Fluorene and Phenanthrene).  
We ran logistic regression models to calculate the multivariable odds ratio ([OR] and 
95% confidence interval [CI]) of self-reported CVD, for each higher urinary OH-PAH quartile 
by using the lowest quartile as the referent. Variables were included in the model if they satisfied 
two conditions: first, a plausible association with the main outcome that is not causal, and 
second, if the percent change of the odds ratio after adjusting for the potential confounder was 
over 10 %. Accordingly, final models were adjusted for age (years), sex (men, women), ethnicity 
(non-Hispanic White, non-Hispanic Black, all others), poverty-income ratio, alcohol drinking 
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(yes/no), diabetes (absent/present), BMI (normal, overweight, obese), total cholesterol (mg/dL), 
serum cotinine (ng/mL) and systolic blood pressure (mm Hg).  
To further ensure that the association is parallel for subgroups, we performed subgroup 
analyses by gender, race/ethnicity, BMI and smoking categories. Sample weights that account 
for the unequal probabilities of selection, oversampling, and nonresponse in the NHANES 
survey were applied for all analyses. Analyses were conducted using SAS (version 9.3, SAS 
Institute, Cary, NC) software. Standard errors were estimated using the Taylor series 
linearization method. 
 
RESULTS 
Table 1 presents baseline characteristics of the study population. About one half of the 
study population was female (49.6%). The majority of the study population was non-Hispanic 
White (72.2%). The arithmetic mean of serum cotinine was 74.4 ng/mL. Table 2 presents the 
sample size, weighted means and percentiles of individual urinary OH-PAH and added 
biomarkers of LMW PAHs. 
Table 3 presents the results of the analyses measuring the association between urinary 
OH-PAH levels and self-reported CVD. Higher quartiles of 1-hydroxynapthalene and additive 
biomarkers of LMW PAHs showed positive association with self-reported CVD, when compared 
to the lowest quartiles. Using urinary levels of OH-PAH as continuous variables, 1-
hydroxypyrene showed statistically significant positive association with self-reported CVD.  
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Table 4 presents the association between urinary OH-PAH and self-reported CVD by 
major sociodemographic characteristics. The positive association between added urinary 
biomarkers of LMW PAHs and self-reported CVD was present among subgroups of gender, 
race, BMI and smoking. The positive association was stronger among the non-obese subgroup 
when compared to the obese group and in current smokers when compared to never and former 
smokers.  P-interaction values for cross-product terms between added urinary biomarkers of 
LMW PAHs and stratifying variables were above >0.10 except for BMI (P=0.002) and smoking 
(P=0.002). Urinary levels of 1-hydroxypyrene, the biomarker of the higher molecular weight 
PAH pyrene, showed positive association with self-reported CVD within subgroups of gender, 
race, BMI and smoking. Some odds ratio failed to reach the conventional levels of statistical 
significance. P-interaction values for cross-product terms between urinary levels of 1-
hydroxypyrene and stratifying variables were above >0.10 except for race (P=0.01). 
 
DISCUSSION 
Urinary levels of 1-hydroxynapthalene, 1-hydroxypyrene and added metabolites of LMW 
PAH showed positive association with self-reported CVD independent of serum cotinine and 
other potential confounders. The positive association was found to be stronger in the non-obese 
subgroup when compared to the obese subgroup and among the current smoker subgroup when 
compared with the never smoker and the former smoker subgroups. Our results are consistent 
with findings from previous occupational studies which reported positive associations between 
exposure to PAHs and ischemic heart diseases [33, 34] and cardiovascular mortality in 
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occupations that include likely exposure to PAHs such as aluminum smelting, motor vehicle 
operators, tar distillation, and asphalt workers.[35, 36] 
Polycyclic aromatic hydrocarbons are a group of chemicals formed by the incomplete 
combustion organic substances.[16, 21, 45] Exposure to PAHs in the environment is widespread. 
Human are usually exposed to mixtures of PAHs.[22] Due to the high cost of detecting parent 
PAH levels in humans, the most commonly used biomarkers of PAH exposure are urinary OH-
PAH metabolites. Urinary OH-PAH biomarkers were used in the current analyses and have been 
found to correlate well with levels of exposure to PAHs in the general populations. [24] 
Several animal studies have reported positive associations between exposure to PAHs, 
oxidative stress and subsequent development of atherosclerosis[28, 30, 50, 51], a major 
underlying risk factor for CVD.[81-83] Upon exposure to PAHs, detoxification occurs, leading 
to the formation of highly reactive intermediates that can interact with the DNA.[28] 
Accordingly, PAH exposure was found to be associated with high levels of PAH-DNA adducts 
in arteries in rats.[30] These effects of PAHs exposure on plaque buildup in animals were found 
to be dose dependent.[50] Moreover, animal studies have suggested that PAHs might also exert 
their atherogenic effect via stimulation of an inflammatory process involving an increased influx 
of proinflammatory cells into these plaques.[30] The role of inflammation as a risk factor for 
atherosclerosis and CVD development has become well established.[7] Several studies have 
shown a positive association between markers of inflammation such as total white blood cell 
count and serum C- reactive protein and CVD.[90, 91]  
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In the current study, we performed subgroup analysis by gender, race/ethnicity, BMI and 
smoking status categories with the intent to examine confounding. In the post-hoc analyses by 
BMI, the positive association between urinary OH-PAH and self-reported CVD was found to be 
stronger in the non-obese subgroup. PAHs are known to have high affinity for lipid-rich tissues 
such as mammary and adipose tissues. [92]  The suggested mechanism for the association 
between PAH exposure and CVD is through inflammatory PAH-DNA adducts buildup in the 
circulatory system. Persons with relatively higher levels of body fat are likely to exhibit 
relatively lower PAH activity in the circulation because of the rapid absorption of PAHs by fatty 
tissue. [92] Accordingly, higher levels of PAHs in the circulation may be related to higher 
inflammatory reaction and eventually the development of cardiovascular diseases. However, it is 
possible that the differences we observed are due to random variability and not true causal 
differences.  Larger studies are needed to confirm if these observed differences in our study are 
consistently observed. Similarly in subgroup analysis by smoking status, current smokers 
showed stronger association between urinary OH-PAH levels and CVD, when compared to 
never and former smokers. This stronger association may be explained by the fact that smoking 
is a major risk factor for cardiovascular morbidity and mortality. The population attributable risk 
of the smoking of tobacco products on CVD risk has been estimated at 26%.[93] 
The main strengths of our study include inclusion of a representative multiethnic sample, 
adequate sample size, and the ability to adjust for potential confounders. The high quality of 
NHANES data and the rigorous standardized methods used in the data collection add to the 
strengths of the study. The main limitation of our study is the cross sectional nature of NHANES 
which does not allow to draw temporal or causal inferences regarding the relationship between 
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PAHs and self-reported CVD. In addition, our study does not have the data to estimate the 
sources of exposure to PAHs. Urinary PAH measurements reflect recent exposure to PAHs if 
there are great differences between the current exposure sources and the past exposure sources 
for each subject. Finally, CVD was ascertained by self-report. Accordingly, some recollection 
bias may exist. However, these biases are likely to be non-differential biases, which would 
minimize any observed association. 
In summary, in a representative cross-sectional sample of the US population, we found 
that higher levels of urinary OH-PAH were positively associated with self-reported CVD. 
However, only 1-hydroxynapthalene, 1-hydroxypyrene and added biomarkers of LMW PAHs 
were statistically significant. The public health importance of our findings is that there is 
evidence, although limited, that background exposure to PAHs is positively associated with CVD 
in the US general population. If our findings are replicated in future larger prospective studies, 
the population-attributable risk of PAH exposure on CVD risk could potentially be high. 
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Table 1. Baseline characteristics of the study population 20-65 years of age with measured 
urinary levels of OH-PAH (n=2661) 
Characteristics 
Mean values ± (Std error of mean) or  
Sample size (weighted percentages)  
Female (%) 1354 (49.6) 
Age (years) 41.0 ± (0.32) 
Race/Ethnicity (%)  
  Non-Hispanic Whites 1332 (72.2) 
  Non-Hispanic Blacks 551 (10.6) 
  Others 778 (17.3) 
Education categories (%)  
  Less than high school 637 (14.4) 
  High school 619 (24.7) 
  Above high school 1405 (60.9) 
Below poverty level (%) 461 (12.6) 
Smoking categories (%)  
  Never  1395 (50.5) 
  Former smokers 559 (21.5) 
  Current  smokers 707 (26.0) 
Alcohol drinking (%)  
  No   742 (23.7) 
  Yes  1919 (76.3) 
Body mass index (%)  
  Normal weight (<25.0 kg/m
2
) 824 (34.3) 
  Overweight (25.0-29.9 kg/m
2
) 901 (31.8) 
  Obese (>30.0 kg/m
2
) 936 (33.9) 
Serum cotinine (ng/mL) 74.4 ± (3.84) 
Total cholesterol (mg/dL) 201.3 ± (1.33) 
Systolic blood pressure (mmHg) 119.3± (0.47) 
CVD (%) 138(4.9) 
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Table 2: Weighted percentiles of OH-PAH (ng/g creatinine) among participants included in the final analysis  
Chemicals Selected percentiles 
 Sample 
size 
Mean  Minimum  10
th
  25
th
  50
th
  75
th
  90
th
   Maximum 
                  
1- Hydroxynaphthalene 2785 41708  50.8  488.7  832.6  1996.3  7120.0  17952   39226536 
2-Hydroxynaphthalene 2794 6263.3  9.2  798.4  1356.5  2885.2  7952.5  16001   404573 
                  
2-Hydroxyfluorene 2767 651.3  2.2  102.8  144.0  245.6  752.1  1740.4   29914 
3-Hydroxyfluorene 2751 334.5  1.2  34.4  52.3  96.7  400.7  1004.8   19084 
                  
1-Hydroxyphenanthrene 2773 214.1  0.7  60.8  89.4  140.9  234.6  370.2   8341.9 
2-Hydroxyphenanthrene 2747 96.6  0.5  22.7  35.7  58.4  101.7  178.4   5069.4 
3-Hydroxyphenanthrene 2745 188.5  0.7  37.6  55.0  90.7  173.8  333.7   20248 
                  
1-Hydroxypyrene 2764 134.4  0.9  22.5  35.8  65.9  136.6  270.4   10014 
                  
Summed LMW PAH biomarkers 2661 50970  508.8  2131.3  3180.1  6207.5  18772  38592   39235478 
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Table 3: Logistic regression: Association of urinary levels of  OH-PAH (ng/g creatinine)  and self-reported cardiovascular disease 
     Chemicals  Sample size Quartile 1 Quartile 2 Quartile 3 Quartile 4 Log-PAH 
 Odds ratio (95% confidence interval)* 
1-Hydroxynaphthalene 2785 1 (Referent) 1.62(0.85, 3.12)  1.44(0.62, 3.35) 2.78(1.35, 5.72) 1.14(0.99, 1.32) 
2-Hydroxynaphthalene 2794 1 (Referent) 1.32(0.70, 2.48) 1.31(0.64, 2.67) 2.12(0.98, 4.58) 1.26(0.98, 1.63) 
       
2-Hydroxyfluorene 2767 1 (Referent) 1.22(0.62, 2.44)  1.17(0.60, 2.28) 2.04(0.99, 4.25) 1.22(0.99, 1.50) 
3-Hydroxyfluorene 2751 1 (Referent) 0.70(0.42, 1.18)  0.74(0.40, 1.38) 1.46(0.78, 2.76) 1.14(0.94, 1.38) 
       
1-Hydroxyphenanthrene 2773 1 (Referent) 0.46(0.25, 0.86)  0.73(0.41, 1.30) 1.25(0.71, 2.18) 1.07(0.86, 1.34) 
2-Hydroxyphenanthrene 2747 1 (Referent) 0.91(0.49, 1.66)  1.25(0.64, 2.42) 1.42(0.78, 2.60) 1.04(0.86, 1.28) 
3-Hydroxyphenanthrene 2745 1 (Referent) 0.68(0.31, 1.47)  1.27(0.63, 2.55) 1.38(0.74, 2.58) 1.10(0.86, 1.41) 
       
1-Hydroxypyrene 2764 1 (Referent) 1.06(0.53, 2.15)  1.21(0.57, 2.57) 1.87(0.89, 3.94) 1.26(1.04, 1.53) 
       
Summed LMW PAH 
biomarkers 
2661 1 (Referent) 1.24(0.66, 2.34)  1.23(0.57, 2.65) 2.27(1.03, 5.02) 1.17(0.96, 1.42) 
*Adjusted for age (years), sex (male/female), race/ethnicity (non-Hispanic White, non-Hispanic Black, others), alcohol (yes, no), BMI (normal 
weight, overweight, obese), income-poverty ratio, serum cotinine (ng/mL), cholesterol (mg/dL), diabetes (present, absent) and systolic blood 
pressure (mmHg). 
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Table 4: Logistic regression: Association of urinary OH-PAH (ng/g creatinine) and self-reported cardiovascular diseases by sociodemographic 
characteristics 
Subgroups  Summed urinary levels LMW PAH biomarkers 1-hydroxypyrene 
 Multivariable odds ratio of CVD p-interaction  Multivariable odds ratio of CVD p-interaction 
Gender*  0.64  0.27 
 Male  1.24(0.88, 1.75)  1.28(1.01, 1.64)  
 Females  1.11(0.92, 1.34)  1.25(0.89, 1.73)  
     
Race-ethnicity*  0.41  0.01 
 Non-Hispanic whites 1.18(0.94, 1.49)  1.35(1.08, 1.69)  
 All others 1.14(0.81, 1.60)  1.03(0.76, 1.41)  
     
Body mass index
+
  0.002  0.26 
Non obese 1.43(1.13, 1.82)  1.39(1.05, 1.82)  
Obese  1.05(0.83, 1.33)  1.15(0.90, 1.47)  
     
Smoking*  0.002  0.15 
Never smokers 1.21(0.93, 1.56)  1.06(0.72, 1.57)  
Former smokers 0.77(0.43, 1.38)  1.14(0.80, 1.63)  
Current smokers 2.59(1.29, 5.19)  1.79(1.06, 3.02)  
* Adjusted for age (years), gender (male/female), race/ethnicity (non-Hispanic White, non-Hispanic Black, others), alcohol intake (yes, no), BMI 
(normal weight, overweight, obese), income-poverty ratio, serum cotinine (ng/mL), cholesterol (mg/dL), diabetes (present, absent) and systolic 
blood pressure (mmHg) except stratified variables 
+ Adjusted for age (years), gender (male/female), race/ethnicity (non-Hispanic White, non-Hispanic Black, others), alcohol intake (yes, no), BMI 
(Kg/m
2
), income-poverty ratio, serum cotinine (ng/mL), cholesterol (mg/dL), diabetes (present, absent) and systolic blood pressure (mmHg). 
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Conclusion  
Cardiovascular disease is the number one cause death and diabetes mellitus is the seventh 
leading cause of death in the US adults. [72] The burden of cardiovascular disease and diabetes 
mellitus is continuing to grow. It has been shown that the traditional risk factors for CVD and 
diabetes may not explain all of the observed risk of these diseases. Environmental pollutants 
have been recently proposed as a novel CVD and diabetes mellitus risk factor in the general 
population. In the current study, urinary biomarkers of the low molecular weight polycyclic 
aromatic hydrocarbons (Naphthalene, Fluorene and Phenanthrene) and to lesser extent the higher 
molecular weight Pyrene  were significantly associated with high serum C-reactive protein, high 
total white blood cell count, and diabetes mellitus independent of serum cotinine, self-reported 
smoking status and other potential confounders. The previous evidence on the association of 
urinary biomarker of polycyclic aromatic hydrocarbons and self-reported cardiovascular disease 
is limited. 
These new results, consistent with previous animal and occupational studies[27], suggest that 
the low background exposure to polycyclic aromatic hydrocarbons may be related to low grade 
inflammation, evident by baseline elevations in serum CRP and total WBC count. The study also 
provides evidence on the associations between low background exposure to polycyclic aromatic 
hydrocarbons and diabetes mellitus and CVD. The mechanism underlying these associations may 
be through chronic low grade inflammation. Low grade inflammation has been implicated in the 
development of atherosclerosis and subsequent development of CVD.[7] Inflammation has been 
also suggested as a risk factor for insulin resistance[6] and subsequent development of diabetes 
mellitus.[8]  
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 Despite the consistency and biological plausibility, the clinical significance of our findings is 
still unknown. Prospective studies are necessary to confirm or refute our findings. Because 
exposure to polycyclic aromatic is widespread in the environment, and due to the high 
prevalence of diabetes and CVD, the population attributable risk due to polycyclic aromatic 
hydrocarbons exposure could be high. Polycyclic aromatic hydrocarbons occur from both natural 
as well as anthropogenic sources. Efforts to decrease the concentration of PAHs in the ambient 
air can be rewarding. Similar policies, such as anti-smoking bans were associated with a 
significant decrease in the incidence of cardiovascular disease.
95, 96
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